Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Zoledronic acid
Drug ID BADD_D02392
Description Zoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].[A203111] Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone.[L13712,L13715,L13721] Zoledronic acid was first described in the literature in 1994.[A203120] Zoledronic acid was granted FDA approval on 20 August 2001.[L13712]
Indications and Usage Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.[L13712,L13715,L13721] Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.[L13712,L13715,L13721]
Marketing Status approved
ATC Code M05BA08
DrugBank ID DB00399
KEGG ID D01968; D08689
MeSH ID D000077211
PubChem ID 68740
TTD Drug ID D0VM2L
NDC Product Code 63415-0532; 0078-0435; 25021-826; 55150-266; 67457-619; 68083-142; 14593-836; 63850-7104; 82920-012; 63323-966; 69367-190; 65372-1117; 17478-327; 71288-806; 62147-0125; 68554-0037; 16729-242; 43598-330; 55150-283; 67457-794; 68001-437; 65129-1144; 0143-9642; 63323-961; 68083-116; 68083-135; 0409-4215; 16714-815; 67457-390; 68083-256; 63126-906; 43598-331; 70860-210; 72266-152; 42533-102; 53104-7622; 65797-0006; 43598-255; 25021-801; 54288-100; 57741-2600; 25021-830; 55111-685; 55111-688
UNII 6XC1PAD3KF
Synonyms Zoledronic Acid | 2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid | CGP 42446A | CGP-42446 | CGP 42446 | CGP42446 | CGP-42'446 | CGP42'446 | CGP 42'446 | Zometa | Zoledronic Acid Anhydrous | Zoledronate
Chemical Information
Molecular Formula C5H10N2O7P2
CAS Registry Number 118072-93-8
SMILES C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Local reaction08.01.03.012---
Loss of consciousness17.02.04.0040.032065%-
Lung disorder22.02.07.001---
Lung infiltration22.01.02.004---
Lymphadenopathy01.09.01.0020.007157%-
Lymphoedema01.09.01.006; 24.09.01.001--
Lymphoma01.12.01.001; 16.20.01.001---
Macular degeneration06.09.03.001---
Malabsorption07.17.01.001; 14.02.01.004--
Malaise08.01.01.0030.182082%
Marasmus14.03.02.0130.004294%-
Mass08.03.05.0030.005726%-
Mastication disorder07.01.06.016; 15.03.05.022; 17.05.03.0060.009161%-
Mastocytosis01.05.01.0170.004294%-
Metastases to liver09.04.02.004; 16.22.02.001---
Metastases to lung16.22.02.002; 22.08.01.005---
Metastases to spine15.09.03.007; 16.22.02.0070.004294%-
Metastatic malignant melanoma16.03.01.002; 23.08.01.002---
Micturition disorder20.02.02.005---
Micturition urgency20.02.02.006--
Migraine17.14.02.001; 24.03.05.0030.034928%-
Mitral valve incompetence02.07.01.002---
Monoplegia17.01.04.003---
Movement disorder17.01.02.0100.050101%-
Mucosal inflammation08.01.06.002---
Muscle atrophy15.05.03.003; 17.05.03.0040.002863%-
Muscle disorder15.05.03.0140.011165%-
Muscle spasms15.05.03.0040.116234%
Muscular weakness15.05.06.001; 17.05.03.0050.066420%
Musculoskeletal pain15.03.04.0070.064988%
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 26 Pages